NCT05204407Completed
Luteolin for the Treatment of People With Schizophrenia
Source: ClinicalTrials.gov · Last updated 22 Apr 2026
Brief summary (registry, in English)
Luteolin is a natural product found in foods such as celery, green pepper, parsley, and chamomile tea. It has been found to have anti-cancer, anti-oxidant, and anti-inflammatory properties. The purpose of this study is to determine if luteolin helps improve symptoms of schizophrenia.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 85 (actual)
- First submitted
- 11 Jan 2022
- Start date
- 13 Jun 2022
- Primary completion date
- 14 Jan 2026
- Lead sponsor
- University of Maryland, Baltimore
- Diseases
- Schizophrenia
- NCT number
- NCT05204407
What you commit to
- Study type: Interventional
- Participants enrolled: 85
- From 13 Jun 2022 to the primary completion date, 14 Jan 2026
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Meets DSM-5 criteria for alcohol or substance misuse (except caffeine and nicotine) within the last 6 months; or a positive baseline urine drug screen. Participants who meet DSM-5 criteria for marijuana misuse - mild will be included in the study
- Currently taking immunosuppressive medications (e.g. oral scheduled corticosteroids, chemotherapy or transplantation or HIV/AIDs associated drugs); or anti-inflammatory medications, including NSAIDs (e.g. ibuprofen, celecoxib, or naproxen) or aspirin \> 81 mg on a daily basis. The use of PRN anti-inflammatory agents will be allowed.
Other illness
- A current infection, including HIV and Hepatitis C; or an organic brain disorder or medical condition, whose pathology or treatment could alter the presentation or treatment of schizophrenia or significantly increase the risk associated with the proposed treatment protocol
Other
- Female participants who are pregnant or nursing
Who the study is looking for
- Either male or female of any race
- Age is 18-60 years old
- Meets DSM-5 criteria for schizophrenia or schizoaffective disorder
- Positive and Negative Syndrome Scale (PANSS) total score of 75 or more OR a Clinical Global Impression severity of illness item score of 4 or more
- Clinically stable
- Treated with the same antipsychotic for at least 60 days and have received a constant therapeutic dose for at least 30 days prior to study entry
- Able to participate in the informed consent process and provide voluntary informed consent
Age in the registry: 18 years to 60 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Maryland Psychiatric Research Center Coordinator of this site? Confirm its status | Baltimore | United States | Unknown status |
| University of California, Los Angeles Coordinator of this site? Confirm its status | Los Angeles | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.